Suggested remit: To appraise the clinical and cost effectiveness of satralizumab (SA-237) within its marketing authorisation for preventing relapses in neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD).
Status Proposed
Process STA 2018
ID number 1319

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
03 October 2019 - 31 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance